At Auspex Pharmaceuticals, we believe that there is a better way to conduct drug development, using a truly enabling yet overlooked approach. The development of innovative medicines can be done more efficiently and more rapidly than has been the norm, and we are convinced we can dramatically reduce the time and expenditure required to advance needed therapeutics to patients – an important consideration in today’s challenging healthcare environment.
Auspex is interested in exploring collaborative discussions to leverage our research expertise and intellectual property portfolio in the development of strategically deuterated medicines. Our objective is to enter into partnerships with premier pharmaceutical companies whose clinical development and commercialization capabilities will help us advance life-changing therapies for our patients.
Auspex is interested in the following types of business partnerships:
- Defined relationships around the Auspex pipeline of clinical programs, including SD-254 for neuropathic pain.
- Clinical Development agreements that will leverage our enabling intellectual property position while providing franchise management and/or competitive entry into important disease areas for our partners. Such programs could be sourced from our development pipeline of over 200 molecules, or from our prospective partners.
- Establishment of creative arrangements in defined therapeutic areas where our combined resources could enable clinical development of novel New Chemical Entities (NCEs) in an accelerated manner.
We firmly believe in the mutual benefits that result from collaborating with knowledgeable and entrepreneurial pharmaceutical partners. We welcome contact from similarly minded companies who seek to engage in this endeavor with Auspex, and who believe that together we can develop innovative medicines for a better tomorrow.
